Literature DB >> 8388205

Uptake of itraconazole by alveolar macrophages.

J R Perfect1, D V Savani, D T Durack.   

Abstract

Itraconazole is a broad-spectrum potent triazole antifungal agent. Its efficacy in treatment cannot always be explained by body fluid drug levels. In this study, itraconazole was shown to accumulate into host cells. Its intracellular accumulation in cells is greater than that of the antibacterial agent clindamycin, which is known for intracellular localization, and the uptake process does not appear to be active. This ability to reach high concentrations intracellularly may be an important property for the in vivo efficacy of itraconazole.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8388205      PMCID： PMC187808          DOI： 10.1128/AAC.37.4.903

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Itraconazole for cryptococcal infection in the acquired immunodeficiency syndrome.

Authors:  M A Viviani; A M Tortorano; P C Giani; C Arici; A Goglio; P Crocchiolo; M Almaviva
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

2.  Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells.

Authors:  J R Perfect; D L Granger; D T Durack
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

3.  Antibiotic uptake by alveolar macrophages.

Authors:  J D Johnson; W L Hand; J B Francis; N King-Thompson; R W Corwin
Journal:  J Lab Clin Med       Date:  1980-03

4.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Experience with itraconazole in cryptococcosis and aspergillosis.

Authors:  M A Viviani; A M Tortorano; M Langer; M Almaviva; C Negri; S Cristina; S Scoccia; R De Maria; R Fiocchi; P Ferrazzi
Journal:  J Infect       Date:  1989-03       Impact factor: 6.072

6.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Authors:  D W Denning; R M Tucker; L H Hanson; J R Hamilton; D A Stevens
Journal:  Arch Intern Med       Date:  1989-10

7.  R 51211 (itraconazole) therapy of murine cryptococcosis.

Authors:  J R Graybill; J Ahrens
Journal:  Sabouraudia       Date:  1984

8.  Membrane transport of clindamycin in alveolar macrophages.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191
  8 in total
  13 in total

1.  Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 3.  Pharmacokinetics/pharmacodynamics of echinocandins.

Authors:  U Theuretzbacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-14       Impact factor: 3.267

Review 4.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  A case report of chronic granulomatous disease presenting with aspergillus pneumonia in a 2-month old girl.

Authors:  Eun Lee; Seak Hee Oh; Ji Won Kwon; Byoung Ju Kim; Jinho Yu; Chan Jeoung Park; Soo Jong Hong
Journal:  Korean J Pediatr       Date:  2010-06-23

7.  In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Authors:  J R Perfect; G M Cox; R K Dodge; W A Schell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 8.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

9.  Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.

Authors:  E Martin; A Stüben; A Görz; U Weller; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro.

Authors:  Fedja Farowski; Oliver A Cornely; Pia Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.